Macular infarction after intravitreal amikacin.
Doft
B H
BH
Barza
M
M
D000583:Amikacin / Q000009:adverse effects* / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002442:Ceftazidime / Q000627:therapeutic use; D009877:Endophthalmitis / Q000188:drug therapy; D015818:Eye Infections, Bacterial / Q000188:drug therapy; D006801:Humans; D007238:Infarction / Q000139:chemically induced*; D015552:Injections, Intralesional; D012171:Retinal Vessels / Q000187:drug effects*; D014822:Vitreous Body
D000900:Anti-Bacterial Agents; D000583:Amikacin; D002442:Ceftazidime